Total Payments
$689.37
2024 Payments
$219.64
Companies
11
Transactions
37
Medicare Patients
1,124
Medicare Billing
$185,442
Payment Breakdown by Category
Food & Beverage$689.37 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $689.37 | 37 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $188.32 | 8 | $0 (2024) |
| Gilead Sciences, Inc. | $119.50 | 8 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $114.42 | 6 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $47.90 | 3 | $0 (2024) |
| PFIZER INC. | $47.22 | 3 | $0 (2023) |
| AbbVie Inc. | $45.33 | 2 | $0 (2021) |
| Madrigal Pharmaceuticals | $33.33 | 2 | $0 (2024) |
| Lilly USA, LLC | $27.83 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $22.58 | 2 | $0 (2019) |
| Alnylam Pharmaceuticals Inc. | $21.91 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $219.64 | 10 | Janssen Biotech, Inc. ($121.26) |
| 2023 | $84.97 | 5 | PFIZER INC. ($47.22) |
| 2022 | $20.85 | 1 | Janssen Biotech, Inc. ($20.85) |
| 2021 | $275.02 | 15 | Janssen Pharmaceuticals, Inc ($114.42) |
| 2020 | $66.31 | 4 | Gilead Sciences, Inc. ($44.40) |
| 2019 | $22.58 | 2 | Merck Sharp & Dohme Corporation ($22.58) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Gastroenterology | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: LIVER DISEASE | ||||||
| 10/07/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: LIVER DISEASE | ||||||
| 09/04/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Immunology | ||||||
| 08/12/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Immunology | ||||||
| 06/28/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Immunology | ||||||
| 06/25/2024 | Biocon Biologics Inc | Hulio (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Rheumatology | ||||||
| 06/05/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $25.90 | General |
| Category: Immunology | ||||||
| 05/23/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: Diabetes | ||||||
| 03/06/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Immunology | ||||||
| 07/11/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/14/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: Gastroenterology | ||||||
| 06/02/2023 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $22.80 | General |
| Category: Immunology | ||||||
| 05/03/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/05/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/02/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Immunology | ||||||
| 10/27/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/05/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Gastroenterology | ||||||
| 09/23/2021 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/23/2021 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug), XARELTO | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/21/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/13/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: IMMUNOLOGY | ||||||
| 08/18/2021 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.08 | General |
| 07/13/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $28.63 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/29/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 314 | 521 | $82,750 | $46,528 |
| 2022 | 4 | 171 | 244 | $42,268 | $29,605 |
| 2021 | 6 | 336 | 514 | $113,453 | $57,650 |
| 2020 | 7 | 303 | 541 | $126,496 | $51,659 |
Total Patients
1,124
Total Services
1,820
Medicare Billing
$185,442
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 134 | 304 | $36,538 | $26,852 | 73.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 57 | $13,321 | $7,892 | 59.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 36 | 52 | $7,313 | $3,526 | 48.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 33 | 49 | $4,106 | $3,017 | 73.5% |
| 43237 | Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | Facility | 2023 | 18 | 19 | $5,018 | $2,795 | 55.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 28 | 29 | $14,251 | $1,504 | 10.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,203 | $942.10 | 42.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 76 | 88 | $21,448 | $15,552 | 72.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 57 | 110 | $13,221 | $9,959 | 75.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 28 | $3,889 | $2,262 | 58.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $3,710 | $1,832 | 49.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 120 | 136 | $41,135 | $24,525 | 59.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 102 | 223 | $40,810 | $21,004 | 51.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 59 | $7,890 | $4,507 | 57.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 55 | $7,381 | $3,508 | 47.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 18 | 21 | $12,145 | $2,244 | 18.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 20 | 20 | $4,092 | $1,862 | 45.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 109 | 117 | $46,470 | $21,974 | 47.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 71 | 214 | $31,348 | $14,240 | 45.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 53 | $10,640 | $5,114 | 48.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 41 | 91 | $7,280 | $3,328 | 45.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 30 | 31 | $22,409 | $3,243 | 14.5% |
| 43246 | Insertion of stomach tube using an endoscope | Facility | 2020 | 14 | 14 | $6,174 | $2,839 | 46.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 21 | $2,175 | $921.48 | 42.4% |
About Dr. Magda Daoud, M.D
Dr. Magda Daoud, M.D is a Gastroenterology healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2012. The National Provider Identifier (NPI) number assigned to this provider is 1992051635.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Magda Daoud, M.D has received a total of $689.37 in payments from pharmaceutical and medical device companies, with $219.64 received in 2024. These payments were reported across 37 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($689.37).
As a Medicare-enrolled provider, Daoud has provided services to 1,124 Medicare beneficiaries, totaling 1,820 services with total Medicare billing of $185,442. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Staten Island, NY
- Active Since 07/31/2012
- Last Updated 05/11/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1992051635
Products in Payments
- STELARA (Biological) $188.32
- XARELTO (Drug) $91.79
- XIFAXAN (Drug) $47.90
- XELJANZ (Drug) $47.22
- HUMIRA (Biological) $45.33
- RESMETIROM (Drug) $33.33
- MOUNJARO (Drug) $27.83
- INVOKANA (Drug) $22.63
- GIVLAARI (Drug) $21.91
- Hulio (Drug) $21.03
- ZINPLAVA (Biological) $11.47
- DIFICID (Drug) $11.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Staten Island
Dr. Sherif Farag, Md, MD
Gastroenterology — Payments: $160,829
Gastroenterology $160,829
Dr. Sherif Andrawes, Md, MD
Gastroenterology — Payments: $92,017
Gastroenterology $92,017
Deepak Vadada, Md, MD
Gastroenterology — Payments: $34,107
Gastroenterology $34,107
Daniel Megna, Md, MD
Gastroenterology — Payments: $14,432
Gastroenterology $14,432
Anu Sampat, Md, MD
Gastroenterology — Payments: $12,199
Gastroenterology $12,199
Richard Fazio, M.d, M.D
Gastroenterology — Payments: $11,738
Gastroenterology $11,738